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SpotlightEpigenome-wide association studies (EWASs) provide a
systematic approach to uncovering epigenetic variants
underlying common diseases. Discoveries have shed
light on novel molecular mechanisms of disease and
enabled the application of epigenetic variants as bio-
markers. Here, we highlight the recent advances in this
emerging line of research and discuss key challenges for
current and future studies.
Many common diseases in humans are mediated by genetic
and environmental factors. Genome-wide association stud-
ies (GWASs) have been instrumental in identifying com-
mon genetic variants associated with a multitude of
complex traits including common diseases. By contrast,
the systematic assessment of epigenetic variation has
lagged behind. Epigenetic modifications of DNA and his-
tone proteins are heritable (re-established) during cell
division and can induce stable changes in the regulation
of gene expression. Technological advances in high-
throughput DNA analysis have facilitated the genome-
wide examination of epigenetic modifications, primarily
DNA methylation, enabling systematic, large-scale associ-
ation testing with disease phenotypes [1,2]. Publications of
such epigenome-wide association studies (EWASs) have
soared in recent years, revealing novel molecular mecha-
nisms of disease (akin to GWASs) but also substantial
challenges in the interpretation of tentative associations.
Below, we discuss what we consider to be the key issues
concerning the assessment of EWAS findings: cellular
heterogeneity, causal inference, and replication of identi-
fied DNA methylation variable positions (MVPs).
Global epigenetic patterns, such as the genome-wide
distribution of DNA methylation marks, vary substantially
across different cell lineages and cell types. Exogenous
(e.g., smoking, diet, and medication) and endogenous
(e.g., senescence) factors, as well as pathogenic (e.g., in-
flammatory) conditions, have an effect on cellular compo-
sition. Therefore, EWASs depend on analytical tools that
determine epigenetic variation with respect to both con-
founding cellular heterogeneity and phenotype of interest.
The importance of adjusting for the proportions of different
cell populations was emphasised by Liu et al. [3] in an
EWAS for rheumatoid arthritis, a common autoimmune1471-4914/
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whole blood. Indeed, whole blood has proven to be the
tissue of choice for most EWASs owing to its ease of
accessibility. Importantly, they found that the proportions
of the major circulating leukocytes differ between cases
and controls. Statistical methods are capable of inferring
and correcting for such cellular heterogeneity, either with
[4] or without [5,6] the use of reference data sets. Following
reference-based adjustment, Liu et al. achieved a substan-
tial reduction of spurious association signals attributed to
cellular heterogeneity. Conversely, the detected changes in
cell type composition based on global epigenetic patterns
between cases and controls may in some studies delineate
disease pathogenesis or progression itself, thereby inform-
ing biomarker discovery (Figure 1).
Epigenetic variation can contribute to the development
of a disease or be a consequence of it (also known as reverse
causality). Distinguishing between the two processes pre-
sents a major challenge for EWASs. In an early EWAS for
type I diabetes, another common autoimmune disease, a
longitudinal cohort consisting of individuals that were
profiled both before and after disease diagnosis and treat-
ment was analysed [7]. Rakyan et al. found evidence of
DNA methylation changes that precede clinical diagnosis,
potentially contributing to the aetiology of overt type I
diabetes. However, large prospective cohorts that enable
the assessment of temporal origins of epigenetic changes
are scarce, highlighting the need for alternative
approaches. To this end, Dick et al. [8] supplemented their
EWAS for body mass index (BMI), a measure of obesity,
with a methylation quantitative trait loci (metQTL) anal-
ysis. This assessed the possibility of the identified MVPs
being driven by genetic variants. The study identified BMI-
associated MVPs at the HIF3A gene locus, and the most
significant MVP was found to have a larger impact on BMI
than previously reported genetic associations at the well-
studied FTO gene locus. Two genetic variants were identi-
fied upstream of HIF3A that showed an independent effect
on DNA methylation levels. However, these genetic variants
were not associated with BMI, suggesting that the increased
DNA methylation levels at the locus are likely to be a
consequence of increased BMI rather than a cause. The
finding that these MVPs were associated with BMI in sub-
cutaneous adipose but not skin tissue further strengthened
this notion. Nonetheless, the identified non-causal epigenet-
ic changes may still be meaningful as diagnostic or prognos-
tic biomarkers. In addition to metQTL analysis, causal
dependency can also be assessed by Mendelian randomisa-
tion that has been specifically adapted for EWAS [11].Trends in Molecular Medicine, October 2014, Vol. 20, No. 10 541
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Figure 1. The relevance of cellular heterogeneity in EWASs. Statistical methods that assess and adjust for the proportions of different cell populations derived from the DNA
methylation profile of a cell have emerged as powerful tools in epigenome-wide association studies (EWASs). Some algorithms do not depend on reference data sets [5,6],
whereas other algorithms use reference data sets consisting of major leukocyte cell types [4]. Additional data sets will likely be integrated once released by the International
Human Epigenome Consortium (http://ihec-epigenomes.org/). In general, the use of reference data sets is preferred because the cellular composition of a sample can be
estimated more accurately. Below, we distinguish between three types of DNA methylation variable positions (MVPs), all of which are informative in different contexts. (A)
Without correction of cellular heterogeneity, identified DNA methylation changes between cases and controls inform the overall heterogeneity of the phenotype of interest
(irrespective of the underlying source and mechanism). (B) If adjustment for confounding cellular heterogeneity is performed, identified MVPs most accurately reflect
methylation changes relevant to the phenotype. Such pheno-MVPs can subsequently be grouped into functionally more relevant differentially methylated regions (DMRs).
(C) The contrast of all MVPs identified (A) with pheno-MVPs (B) may further characterise the disease state. For example, in addition to epigenetic changes that are related to
the phenotype, an increase in lymphocyte populations may offer valuable clues to the immunobiology of the disease state [4]. Indeed, MVPs attributed to differential cell
type distribution (termed ct-MVPs) may also shed light on the potential involvement of additional (or thus far disregarded) cell types in disease pathogenesis.
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and BMI [8] stand out due to the sequential replication of
the significant MVPs, which involved large numbers of
samples and independent cohorts. In recent EWASs, the
discovery cohort has usually been profiled using the Illu-
mina Infinium HumanMethylation450 BeadChip (‘450K
array’), an array-based platform that can probe more than
485,000 DNA methylation marks across the genome. By
contrast, the platforms selected for replication vary but are
usually low-throughput. As the field matures, analogous to
GWASs, 450K array data sets will be generated for differ-
ent sample cohorts of the same disease, empowering col-
laborative replication efforts and meta-analyses of EWASs.
Alternatively, methylated DNA immunoprecipitation fol-
lowed by deep sequencing (MeDIP-seq) offers a higher-
density approach, capturing disease-relevant DNA meth-
ylation changes not interrogated by the sparse 450K array
[9]. This approach is currently being applied to a large
cohort of 5,000 twins discordant for various phenotypes
(http://www.epitwin.eu/).
The study by Dick et al. [8] as well as an EWAS for
multiple sclerosis, an inflammatory disease of the central
nervous system [10], explored the potential functional im-
pact of the identified epigenetic changes. Huynh et al. [10]542performed RNA-sequencing in brain samples collected from
multiple sclerosis patients and healthy controls. The
authors identified genes with coordinated variation in
DNA methylation and gene expression, following the dogma
of reduced methylation at gene promoters and increased
gene expression, and vice versa. Looking ahead, epigenetic
changes will likely be functionally tested using the much-
publicised genome-editing tools CRISPR/Cas9 and TALEN.
Generally, such follow-up experiments add confidence and
interpretability to the MVPs discovered through EWASs.
Taken together, in EWASs (and in stark contrast to
GWASs) we advise caution with respect to the cellular
heterogeneity of sample material and causal inference of
the identified epigenetic changes. Nevertheless, we pro-
pose that an EWAS is a valuable approach for uncovering
novel molecular mechanisms of disease, and identifying
diagnostic and prognostic biomarkers.
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